SCHEMBL383535

SCHEMBL383535

O=C(O)c1ccc(Cl)cc1Nc1cccc(Br)c1

nearest known ligand 0.74

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 14/20 0.74
GRIK2 Q13002 2/20 0.74
AKR1C3 P42330 3/20 0.59
AKR1C2 P52895 3/20 0.59
MPO P05164 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
GFER P55789 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
USP2 O75604 1/20 0.50
PABPC1 P11940 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6551809 0.88 AKR1C3 (0.72) GRIK1GRIK2AKR1C3AKR1C2MPO
SCHEMBL31060427 0.88 AKR1C3 (0.72) GRIK1GRIK2AKR1C3AKR1C2MPO
SCHEMBL6431740 0.85 GRIK1 (1.00) GRIK1GRIK2MEN1KMT2A
SCHEMBL9515604 0.85 GRIK1 (0.69) GRIK1GRIK2AKR1C3AKR1C2MEN1
SCHEMBL15397409 0.83 AKR1C3 (0.60) GRIK1GRIK2AKR1C3AKR1C2MPO
SCHEMBL384593 0.82 FABP4 (0.65) GRIK1GRIK2AKR1C3AKR1C2MPO
SCHEMBL31500236 0.80 AKR1C3 (0.70) GRIK1AKR1C3AKR1C2MEN1KMT2A
SCHEMBL901641 0.80 AKR1C3 (0.80) AKR1C3AKR1C2MEN1KMT2ALMNA
SCHEMBL28404353 0.80 AKR1C3 (0.81) GRIK1AKR1C3AKR1C2MEN1KMT2A
SCHEMBL29835007 0.80 MPO (0.81) GRIK1AKR1C3AKR1C2MPOMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1330456-B8 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-02-08 EP disclosed
EP-1330456-B9 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-01-25 EP disclosed
EP-1330456-B9 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-01-25 EP disclosed
EP-1330456-B1 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2011-06-15 EP disclosed
EP-1330456-B1 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2011-06-15 EP disclosed
US-7115619-B2 N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-10-03 US disclosed
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-04-01 US disclosed
EP-1330456-A2 N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2003-07-30 EP disclosed
WO-2002030932-A2 N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents TERT, MKI67, NQO2 GRIK1 4275/4885GRIK2 4387/4885AKR1C3 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.